Finch Therapeutics Group, Inc.
FNCHDelisted Oct 31, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001733257
Finch Therapeutics Group, Inc. was delisted on Oct 31, 2024; its insiders filed their last Form 4 on Jun 10, 2024; no institution reported holding it in 13F filings for Q3 2024; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 0
- Q3 2024, −1 vs. previous quarter
- 13F value
- $0
- Reported value at the end of Q3 2024
- Superinvestors holding
- 0
- At the end of Q3 2024
Superinvestors holding FNCH, Q3 2024
No superinvestor reported holding FNCH at the end of Q3 2024.
Latest insider trades
Open-market purchases and sales by Finch Therapeutics Group, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 29, 2024 (view filing) | Mar 28 | 1 day | Smisek Jeffery ADirector | SSale | −6.64K | $2.57 | −$17.1K | −100.0%0 after | |
| Mar 29, 2024 (view filing) | Mar 28 | 1 day | Smisek Jeffery ADirector | SSale | −1.60K | $2.61 | −$4.18K | −19.7%6.51K after | |
| Nov 27, 2023 (view filing) | Nov 22 | 5 days | Smisek Jeffery ADirector | SSale | −1.47K | $3.64 | −$5.35K | −18.1%6.64K after | |
| Jun 9, 2023 (view filing)4:15 PM ET | Jun 9 | Same day | Graf Susan EDirector | PPurchase | +5.01K | $0.27 | +$1.35K | New position5.01K after | |
| Feb 23, 2023 (view filing)4:05 PM ET | Feb 21 | 2 days | Blaustein MarcChief Operating Officer | SSale | −4.62K | $0.38 | −$1.76K | −14.2%28.0K after | |
| Oct 25, 2022 (view filing) | Oct 21 | 4 days | Blaustein MarcChief Operating Officer | SSale | −3.64K | $1.39 | −$5.05K | −10.0%32.6K after | |
| Oct 25, 2022 (view filing) | Oct 21 | 4 days | Vittiglio JosephChief Business & Legal Officer | SSale | −3.64K | $1.39 | −$5.05K | −10.4%31.4K after | |
| Dec 22, 2021 (view filing) | Dec 20 | 2 days | Haft NicholasDirector | PPurchaseCommon Stock, $0.001 par value per share | +63.9K | $10.18 | +$650.0K | +1.6%4.06M after |
Top 10 13F holders, Q3 2024
The largest institutional positions in Finch Therapeutics Group, Inc. at the end of Q3 2024; share changes are against Q2 2024.
No institution reported holding FNCH in 13F filings for Q3 2024.